Thermo Fisher Scientific have spearheaded the development and democratization of next-generation sequencing, a technology that has fueled research in precision oncology and will play a key part in its broad implementation for patients. Dr. Garret Hampton, president of the Clinical Sequencing Division will talk current and future Oncomine IVD and companion diagnostics (CDx) solutions and namely about plans for IVD submissions of future Oncomine Dx Express Test on Genexus System.